Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

UCB SA (UCBJF)

Other OTC - Other OTC Delayed Price. Currency in USD
78.950.00 (0.00%)
At close: 02:49PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close78.95
Open78.95
Bid0.00 x 0
Ask0.00 x 0
Day's Range78.95 - 78.95
52 Week Range68.30 - 122.90
Volume150
Avg. Volume50
Market Cap15.042B
Beta (5Y Monthly)0.38
PE Ratio (TTM)17.37
EPS (TTM)4.55
Earnings DateN/A
Forward Dividend & Yield1.37 (1.88%)
Ex-Dividend DateApr 29, 2022
1y Target EstN/A
  • PR Newswire

    Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

    UCB, a global biopharmaceutical company, today announced that Annals of the Rheumatic Diseases has published 24-week results from the Phase 3 BE MOBILE 1 and BE MOBILE 2 studies, evaluating the efficacy and safety of bimekizumab in the treatment of adults with active axial spondyloarthritis (axSpA), including active non-radiographic axial spondyloarthritis (nr-axSpA; BE MOBILE 1) and active ankylosing spondylitis (AS; BE MOBILE 2).1

  • PR Newswire

    UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review

    UCB, a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's filing to review a Biologic License Application (BLA) for its investigational treatment rozanolixizumab, and that the Agency has granted Priority Review.1 Rozanolixizumab is a subcutaneous (SC) monoclonal antibody targeting the neonatal Fc receptor (FcRn) for the treatment of adults with generalized myasthenia gravis (gMG) who are anti-acetycholine receptor (AChR)

  • GlobeNewswire

    Praxis Precision Medicines and UCB Announce Epilepsy Research Collaboration

    BOSTON, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company, and UCB (EURONEXT BRUSSELS: UCB), a global biopharmaceutical company, today announced a strategic collaboration, based upon Praxis’ PRAX-020 program, for the discovery of small molecule therapeutics as potential treatments of KCNT1 related epilepsies. “We are excited to partner with UCB, a global leader in epilepsy drug development, as we work together toward a n

Advertisement
Advertisement